Capivasertib
Capivasertib (AZD5363) is an orally active, pan-AKT inhibitor targeting Akt1, Akt2, and Akt3 with low nanomolar potency. It demonstrates antitumor efficacy in preclinical models of breast cancer and is widely used in research exploring AKT signaling in oncology, supported by both in vitro and in vivo studies.
Product Specifications
CAS Number
1143532-39-1
Product Name Alternative
Inhibitor, inhibit, mTOR (p70S6K), Akt, AZD 5363, Autophagy, AZD5363, AZD-5363, Akt1, Akt2, Akt3, Capivasertib, Protein kinase B, PKB, PKA
Field of Research
Cell Biology, Signal Transduction
Purity
97.59% (May vary between batches)
Solubility
DMSO:130 mg/mL (303.09 mM) ; Ethanol:1 mg/mL (2.33 mM) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:8 mg/mL (18.65 mM) ; H2O:Insoluble
Smiles
NC1 (CCN (CC1) c1ncnc2[nH]ccc12) C (=O) N[C@@H] (CCO) c1ccc (Cl) cc1
Molecular Formula
C21H25ClN6O2
Molecular Weight
428.92
References & Citations
Pubmed id
40360883
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CYTB, ID (MT-CYB, COB, CYTB, MTCYB, Cytochrome b, Complex III subunit 3, Complex III subunit III, Cytochrome b-c1 complex subunit 3, Ubiquinol-cytochrome-c reductase complex cytochrome b subunit) (MaxLight 550) discontinued
DCTN4 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)